NEW YORK (GenomeWeb News) – Luminex and Becton Dickinson’s Diagnostics-TriPath division have struck a development and supply agreement for biomarker-based cancer tests, Luminex said yesterday.
BD Diagnostics-TriPath will use Luminex’s multiplexing xMAP Technology, which allows multiple, simultaneous tests to be conducted using one sample, to develop diagnostic tests for certain cancers that BD will market.
Luminex said that BD plans to expand its cancer test program to include “a broad menu” of new diagnostic tests for solid tumor cancers using Luminex’s xMAP Technology.
"We believe providing biomarker testing in a multiplex format would allow detection of cancer at an earlier stage,” which could lead to better patient outcomes, BD Diagnostics-TriPath VP and GM Wayne Brinster said in a statement.
This morning at the UBS Global Life Sciences Conference in New York, Luminex CEO Patrick Balthrop said he views the agreement with BD, a leader in the flow cytometry market, as a validation of the flow-cytometry-based xMAP platform.
Balthrop did not disclose the specific cancers that would be targeted in the collaboration, but said that they would be those that are “most difficult to diagnose.”